TeloVISION LLC aims to develop a minimally-invasive, affordable point-of-care testing (POCT) platform and solutions for early metastasis diagnosis, quick monitoring of cancer progression and recurrence, and early prediction of therapeutic efficacy and drug resistance. The company's flagship project, CeloVISION, is a manually operated, disposable, in-vitro POCT device for simultaneous isolation, enrichment, detection, and enumeration of circulating tumor cells (CTCs). The presence and the number of CTCs can be read by the device in 40 minutes, allowing early diagnosis and timely treatment adjustment. It potentially liberates physicians from delays, improves turnaround of inpatients, reduces the length of clinic/hospital stay and cost of care, and importantly, improves cancer patientâs survival rate.
